CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an <i>ESMO Open-Cancer Horizons</i> pro and con discussion.

ABSTRACT: In December 2017, ESMO Open-Cancer Horizons convened a round-table discussion on the background and latest data regarding cyclin-dependent kinase (CDK)4/6 inhibitors with endocrine therapy (ET) in the treatment of endocrine-sensitive breast cancer (BC). A review on this discussion was published in summer 2018 (https://esmoopen.bmj.com/content/3/5/e000368).Endocrine-sensitive BC with non-visceral disease and limited spread of the metastases.Endocrine-sensitive BC with non-life-threatening visceral involvement. Several open questions were identified, which led to a second ESMO Open discussion on CDK4/6 inhibitors, taking place in December 2018 and covered in this article. The panel discussed two important clinical scenarios and the pro and cons of a treatment approach with CDK4

SUBMITTER: Awada A 

PROVIDER: S-EPMC6863664 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature